Supriya D. Mahajan PhD, MPH
Supriya D. Mahajan
PhD, MPH
Associate Professor
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Apoptosis and cell death; Bioinformatics; Endocrinology; Gene Expression; Gene Therapy; Genomics and proteomics; Immunology; Molecular and Cellular Biology; Molecular Basis of Disease; Neurobiology; RNA; Viral Pathogenesis
Professional Summary:
Dr. Mahajan has established herself as an investigator in the area of neuropathogenesis of HIV-1 in the context of drug abuse. She has established 2D and 3D Blood Brain Barrier (BBB) models, that allow
studying mechanisms of BBB pathophysiology, examine BBB integrity and evaluate permeability of neurotherapeutics across the BBB. She investigates the role of a unique key signaling molecule in the dopaminergic pathway called DARPP-32, that impacts drug addiction, depression and other neurological disorders. Her focus has always been on collaborative, interdisciplinary partnerships between various Departments within UB that include the Institute of Lasers, Photonics and Biophotonics, Research Institute of Addiction, Dept of Computer Science and Engineering, Dept of Pharmaceutical sciences, Dept of Oral Biology and the Department of Bioengineering and also multiinstitutional collaborations with University of Rochester Medical Center and SUNY Albany. This inclusive strategy has facilitated the emergence of a robust, innovative clinical translational research program that continues to grow steadily. Dr Mahajan has obtained independent research funding from NIDA, NSF iCorp, Pharmaceuticals like Pfizer, Shire, Global- CRDF, US- Fulbright and other Private Foundations such as Dr. Louis Skalrow Memorial trust. Dr. Mahajan is Director of Research of the Division of Allergy, Immunology & Rheumatology. She supervises the research training of the Allergy fellows, Medical residents, graduate and undergraduate students. Dr. Mahajan has presented her research work at National and International conferences and was an invited speaker at several seminars and colloquiums. She has authored over 108 publications in several top quality peer reviewed journals and has thus demonstrated a high level of scholarly productivity. She is a reviewer and an adhoc member of the editorial board of several journals in her field.
The following is a brief synopsis of her research interests.
HIV neuropathogenesis in the context of drug abuse:
We proposed that Opiates act as co-factors in the pathogenesis of HIV-1 infections by directly suppressing immune functions of the host through interactions with mu-opioid receptors on lymphocytes. Exacerbation of HIV encephalopathy (HIVE) is observed with opiate abuse. The mechanisms underlying HIVE are currently undetermined however, they likely to include the generation of endogenous neurotoxins combined, perhaps synergistically, with bioreactive HIV-1 envelope proteins. We believe that these proposed mechanisms may work through a common signal transduction mechanism activating dopamine D1 receptors in the nucleus accumbens of the brain. Opiate abuse by HIV-1 infected subjects may exacerbate the progression of HIVE as a consequence of the combined effects of HIV-1 induced neurotoxins plus opiate induced increases in the D1 receptor activation. We hypothesize that the dopaminergic signaling pathway is the central molecular mechanism that integrates the neuropathogenic activities of both HIV-1 infections and the abuse of opiate drugs. In this context our investigation is focused on the DARPP-32 signalling pathway. Addictive drugs act on the dopaminergic system of the brain and perturb the function of the dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32 kD (DARPP-32). DARPP-32 is critical to the pathogenesis of drug addiction by modulating both transcriptional and post-translational events in different regions of the brain. DARPP-32 is localized within neurons containing dopamine receptors and is a potent inhibitor of another key molecule in the dopaminergic signaling pathway, protein phosphatase 1 (PP-1). We propose that the sustained silencing of DARPP-32 gene expression using specific siRNA delivered to the brain is an innovative approach for the treatment of drug addiction. The specific challenge of the proposed project is the non-invasive delivery of biologically stable, therapeutic siRNA molecules to target cells within the brain. We are developing biocompatible nanoparticles to both protect DARPP-32 specific siRNA against degradation and deliver it from the systemic circulation across the BBB to specific dopaminergic neurons in the brain of patients with opiate addictions.
BBB Research:
While examining neuropathogenesis of HIV, we became interested in the role of the blood-brain barrier (BBB) in HIV neuropathogenesis with the objective of developing therapeutic interventions to prevent and limit the progression of HIV associated neurological disease. The blood-brain barrier is an intricate cellular system composed of vascular endothelial cells and perivascular astrocytes that restrict the passage of molecules between the blood stream and the brain parenchyma. The in-vitro BBB models allow examining permeability of virus, effects of drugs of abuse on BBB permeability, mechanisms of BBB transport, and tight junction modulation. Our goal remains to determine the impact of current and potential CNS antiretrovirals, psychopharmacologic, and other medications on the integrity of the BBB in HIV associated neurological disorder and other neurodegenerative diseases. Additionally, we also investigate mechanisms that underlie drugs of abuse induced neuronal apoptosis.
Systems biology approach:
We expanded our investigation to include functional genomic/proteomic NGS analyses that allowed characterization of gene/ protein modulation in response to a drug stimulus or under a specific disease condition. We developed an expertise in these large-scale genomic and proteomic studies and the genomic studies helped identify key genes that underlie molecular mechanisms in drug addiction, HIV diseases progression, and allowed examination of the interplay of genes and environmental factors. The proteomic studies confirmed the presence of specific proteins that regulate key biological processes in drug addiction and HIV diseases progression. Recently, We have expanded my research program to include microbiome analyses and incorporated the utility of the computational drug discovery platform (CANDO) model that allows studying interaction between protein structures from microbiome genomes and determine the interactions that occur between them and small molecules (drugs and human/bacterial metabolites that are already a part of or continue to be added to the CANDO library. Using the CANDO Platform we are able to do the hierarchical fragment-based docking with dynamics between those compounds/drugs and the microbiome proteins/proteomes to determine which ones of the drugs and metabolites will work most efficaciously in patients using specific drugs.
NanoMedicine:
We have developed a strong program in nanomedicine and have initiated several interdisciplinary clinical translational research focused collaborations that include 1) Nanotechnology based delivery systems to examine antitretroviral transport across the BBB; 2) Nanotherapeutics using siRNA/Plasmid delivery to specific regions in the brain to target various genes of interest specifically those pertaining to the dopaminergic pathway that result in the modulation of behavioral response which we observed in animal models of addiction/depression; 3) Biodistribution studies of various nanotherapeutic formulations using PET small animal imaging. Additionally, We are also focused on exploring epigenetic mechanisms that under drug addiction and mechanisms that underlie oxidative stress in neurodegenerative diseases.
Education and Training:
- MPH, Community Health & Health Disparities, University at Buffalo (2020)
- Fellowship, Immunology, University at Buffalo, The State University of New York (2001)
- Fellowship, Metabolism/Endocrinology, Case Western Reserve University (CWRU) (1998)
- PhD, Metabolism/Endocrinology, All India Institute of Medical Sciences (AIIMS) (1995)
- MD, University of Bombay, India (1987)
- BS, University of Bombay, India (1985)
Employment:
- Associate Professor, Medicine, University at Buffalo
- Adjunct Associate Professor, Department of Chemical and Biological Engineering, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2019-present)
- Research Associate Professor, Medicine, University at Buffalo, The State University of New York Jacobs School of Medicine & Biomedical Sciences (2014-present)
- Research Assistant Professor, Medicine, University at Buffalo, The State University of New York Jacobs School of Medicine & Biomedical Sciences (2002–2014)
- Postdoctoral Research Associate, Medicine, University at Buffalo, The State University of New York Jacobs School of Medicine & Biomedical Sciences (1998–2001)
- Post Doctoral Fellow, Case Western Reserve University, Cleveland OH (1995–1998)
- Pre-doctoral Research Fellow, All India Institute of Medical Sciences (1990–1995)
- Research Fellow, Indo-USA NIH Funded Senior Fulbright Project (1993–1994)
- Research Assistant, All India Institute of MedicalSciences (1988–1990)
Awards and Honors:
- CRDF-Global Mentorship Award (2019)
- Faculty Excellence Award (2018)
- Best Research Mentor. CSTEP :Program (2017)
- UB’s Faculty Internationalization Fund (2013)
- US Fulbright Senior Scholar (2012) (2012)
- NIDA Cutting-Edge Basic Research Awards (CEBRA) (2011)
- NIDA Scholarship (2011)
- NIDA Scholarship (2011)
- Young Investigator Travel Award (2008)
- Young Investigator award - International AIDS Society (2007)
- College on Problems of Drug Dependence Young Investigator Award (2005)
- International Union of Immunology Societies (IUIS) (2004)
- Society for Neuro-Immune Pharmacology (2003)
- INSERM Award (1992)
- Travel Award from the Department of Science and Technology, Government of India (1990)
Research Expertise:
- Blood Brain Barrier Research: We have validated both the 2 and 3 dimensional human in-vitro BBB models in my laboratory, that allowed examining permeability of virus, effects of drugs of abuse on BBB permeability, mechanisms of BBB transport, and tight junction modulation. My goal remains to determine the impact of current and potential CNS antiretrovirals, psychopharmacologic, and other medications on the integrity of the BBB in HIV associated neurological disorder and other neurodegenerative diseases. Additionally, I also investigate mechanisms that underlie drugs of abuse induced neuronal apoptosis.
- HIV Neuropathogenesis: Dr. Mahajan has expertise in the area of HIV neuropathogenesis specifically in the context of drug abuse.
- Nanomedicine: Nanotherapeutics for drug and gene delivery.
- Systems Biology applications: Systems Biology analyses that allowed characterization of gene/ protein modulation in response to a drug stimulus or under a specific disease condition. I developed an expertise in these large-scale genomic and proteomic studies and the genomic studies helped identify key genes that underlie molecular mechanisms in drug addiction, HIV diseases progression, and allowed examination of the interplay of genes and environmental factors. The proteomic studies confirmed the presence of specific proteins that regulate key biological processes in drug addiction and HIV diseases progression.I expanded my investigations to include functional genomic/proteomic analyses that allowed characterization of gene/ protein modulation in response to a drug stimulus or under a specific disease condition. I developed an expertise in these large-scale genomic and proteomic studies and the genomic studies helped identify key genes that underlie molecular mechanisms in drug addiction, HIV diseases progression, and allowed examination of the interplay of genes and environmental factors. The proteomic studies confirmed the presence of specific proteins that regulate key biological processes in drug addiction and HIV diseases progression. Recently I have expanded my research program to include microbiome analyses and incorporated the utility of the computational drug discovery platform (CANDO) model that allows studying interaction between protein structures from microbiome genomes and determine the interactions that occur between them and small molecules (drugs and human/bacterial metabolites that are already a part of or continue to be added to the CANDO library. Using the CANDO Platform we are able to do the hierarchical fragment-based docking with dynamics between those compounds/drugs and the microbiome proteins/proteomes to determine which ones of the drugs and metabolites will work most efficaciously in patients using specific drugs.
Research Centers:
- Clinical and Translational Research Center (CTRC)
Grants and Sponsored Research:
- September 2020–August 2025
Inhibition of Radiation-Induced Coronary Microvascular Disease.
NIH
Role: Co-Investigator
$1,750,000 - January 2018–December 2023
Biomarkers for Type III Hereditary Angioedema
Takeda originally Shire
Role: Co-Investigator
$275,000 - January 2020–March 2022
Oral Microbiome in HIV+ patients with Thrush.
Buffalo Blue Sky Award UB VPR Office
Role: Principal Investigator
$35,000 - February 2019–January 2022
A novel phase and spectroscopic imaging technique to evaluate mitochondrial dynamics
National Institute of Drug Abuse (NIDA)
Role: Principal Investigator
$1,200,000 - June 2020–October 2020
Mitochondrial dynamics in SARS-CoV-2 spike protein treated human CNS cells: Implications for COVID19 induced CNS hypoxia
SUNY Research Seed Grant Program
Role: Principal Investigator
$5,000 - July 2010–June 2013
Innovative Nanotherapy for Drug Addiction.
Cutting-Edge Basic Research Awards (CEBRA)
Role: Principal Investigator
$250,961 - February 2008–July 2012
Effect of the SDF-1 3‘A Genetic variant on emergence of X4 tropism in Long Term Non-Progressors of HIV-1 disease.
Pfizer
Role: Principal Investigator
$38,600 - February 2012–June 2012
Genetic basis for the increased incidence of HIV-1 associated lipodystrophy in the Indian HIV-1 subtype C patient cohort.
US Scholars Core Fulbright Program
Role: Principal Investigator
Patents:
- Method of using gold nanorods-siRNA complexes Bioconjugation of Gold nanorods and DARPP-32 siRNA (2011)
Journal Articles:
- Pliss A, Kuzmin AN, Prasad PN, Mahajan SD. (2022) Mitochondrial Dysfunction: A Prelude to Neuropathogenesis of SARS-CoV-2. ACS chemical neuroscience (Feb), 13(3): 308-312. doi:10.1021/acschemneuro.1c00675
- Schmitt RR, Mahajan SD, Pliss A, Prasad PN. (2021) Small molecule based EGFR targeting of biodegradable nanoparticles containing temozolomide and Cy5 dye for greatly enhanced image-guided glioblastoma therapy. Nanomedicine : nanotechnology, biology, and medicine (Dec), 41: 102513.
- Clough E, Inigo J, Chandra D, Chaves L, Reynolds JL, Aalinkeel R, Schwartz SA, Khmaladze A, Mahajan SD. (2021) Mitochondrial Dynamics in SARS-COV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology (Dec), 16(4): 770-784. doi:10.1007/s11481-021-10015-6
- Schmitt RR, Kaliyappan K, Muthaiah VPK, Ignatowski TA, Prasad PN, Mahajan SD. (2021) Blast-induced injury responsive relative gene expression of traumatic brain injury biomarkers in human brain microvascular endothelial cells. Brain research (Nov), 1770: 147642.
- Hsiao CB, Bedi H, Gomez R, Khan A, Meciszewski T, Aalinkeel R, Khoo TC, Sharikova AV, Khmaladze A, Mahajan SD. (2021) Telomere Length Shortening in Microglia: Implication for Accelerated Senescence and Neurocognitive Deficits in HIV. Vaccines (Jul), 9(7). doi:10.3390/vaccines9070721
- Sharma A, Kumar A, Li C, Panwar Hazari P, Mahajan SD, Aalinkeel R, Sharma RK, Swihart MT. (2021) A cannabidiol-loaded Mg-gallate metal-organic framework-based potential therapeutic for glioblastomas. Journal of materials chemistry. B (Mar), 9(10): 2505-2514.
- Mahajan SD, Homish GG, Quisenberry A. (2021) Multifactorial Etiology of Adolescent Nicotine Addiction: A Review of the Neurobiology of Nicotine Addiction and Its Implications for Smoking Cessation Pharmacotherapy. Frontiers in public health (Jan), 9: 664748. doi:10.3389/fpubh.2021.664748
- Mammen MJ, Ali J, Aurora A, Sharma UC, Aalinkeel R, Mahajan SD, Sands M, Schwartz SA. (2021) IL-17 Is a Key Regulator of Mucin-Galectin-3 Interactions in Asthma. International journal of cell biology (Jan), 2021: 9997625. doi:10.1155/2021/9997625
- Mahajan SD, Ordain NS, Kutscher H, Karki S, Reynolds JL. (2021) HIV Neuroinflammation: The Role of Exosomes in Cell Signaling, Prognostic and Diagnostic Biomarkers and Drug Delivery. Frontiers in cell and developmental biology (Jan), 9: 637192. doi:10.3389/fcell.2021.637192
- Hua W, Wang S, Wang X, Shao Y, Wang Y, Ye J, Su B, Jiang T, Zhang T, Wu H, Liu A, Li Q, Mahajan SD, Li Z, Sun L, Dai L. (2021) Neuropsychiatric Adverse Events During 12 Months of Treatment With Efavirenz in Treatment-Naïve HIV-Infected Patients in China: A Prospective Cohort Study. Frontiers in psychiatry (Jan), 12: 579448. doi:10.3389/fpsyt.2021.579448
- Kumar A, Sharma A, Chen Y, Jones MM, Vanyo ST, Li C, Visser MB, Mahajan SD, Sharma RK, Swihart MT. (2020) Copper@ZIF-8 Core-Shell Nanowires for Reusable Antimicrobial Face Masks. Advanced functional materials (Dec)2008054. doi:10.1002/adfm.202008054
- Singh A, Kutscher HL, Bulmahn JC, Mahajan SD, He GS, Prasad PN. (2020) Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV. Nanomedicine : nanotechnology, biology, and medicine (Apr), 25: 102172. doi:10.1016/j.nano.2020.102172
- Singh A, Mahajan SD, Kutscher HL, Kim S, Prasad PN. (2020) Curcumin-Pluronic Nanoparticles: A Theranostic Nanoformulation for Alzheimer's Disease. Critical reviews in biomedical engineering (Jan), 48(3): 153-168.
- Reynolds JL, Mahajan SD. (2019) Transmigration of Tetraspanin 2 (Tspan2) siRNA Via Microglia Derived Exosomes across the Blood Brain Barrier Modifies the Production of Immune Mediators by Microglia Cells. J Neuroimmune Pharmacol (Dec).
- Singh A, Kim BK, Mackeyev Y, Rohani P, Mahajan SD, Swihart MT, Krishnan S, Prasad PN. (2019) Boron-Nanoparticle-Loaded Folic-Acid-Functionalized Liposomes to Achieve Optimum Boron Concentration for Boron Neutron Capture Therapy of Cancer. Journal of biomedical nanotechnology (Aug), 15(8): 1714-1723.
- Sharma A, Yadav A, Gupta N, Sharma S, Kakkar R, Cwiklinski K, Quaye E, Mahajan SD, Schwartz SA, Kumar Sharma R. (2019) Multifunctional mesoporous curcumin encapsulated iron-phenanthroline nanocluster: A new Anti-HIV agent. Colloids and surfaces. B, Biointerfaces (Aug), 180: 289-297.
- Anu Sharma, Anita Yadav, Sandeep Sharma, Rita Kakkar, Katherine Cwiklinski, Elizabeth Quaye, Supriya Mahajan, Stanley A. Schwartz, Rakesh Kumar Sharma. (2019) Multifunctional mesoporous curcumin encapsulated iron-phenanthroline nanocluster: A new Anti-HIV agent. Colloids and Surfaces B: Biointerfaces (Aug), 180: 289-297.
- D'Brant LY, Desta H, Khoo TC, Sharikova AV, Mahajan SD, Khmaladze A. (2019) Methamphetamine-induced apoptosis in glial cells examined under marker-free imaging modalities. Journal of biomedical optics (Apr), 24(4): 1-10. doi:10.1117/1.JBO.24.4.046503
- Dai L, Liu A, Zhang H, Wu H, Zhang T, Su B, Shao Y, Li J, Ye J, Scott SR, Mahajan SD, Schwartz SA, Yu H, Sun L. (2019) Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study. Current HIV research (Jan), 17(5): 324-334.
- Sharma UC, Sonkawade SD, Baird A, Chen M, Xu S, Sexton S, Singh AK, Groman A, Turowski SG, Spernyak JA, Mahajan SD, Pokharel S, Sharma U. (2018) Effects of a novel peptide Ac-SDKP in radiation-induced coronary endothelial damage and resting myocardial blood flow. Cardiooncology (Dec), 4.
- Patel S, Parikh NU, Aalinkeel R, Reynolds JL, Dmello R, Schwartz SA, Mahajan SD. (2018) United States National Trends in Mortality, Length of Stay (LOS) and Associated Costs of Cognitive Impairment in HIV Population from 2005 to 2014. AIDS Behav (Oct), 22(10): 3198-3208.
- Sharikova AV, Quaye E, Park JY, Maloney MC, Desta H, Thiyagarajan R, Seldeen KL, Parikh NU, Sandhu P, Khmaladze A, Troen BR, Schwartz SA, Mahajan SD. (2018) Methamphetamine Induces Apoptosis of Microglia via the Intrinsic Mitochondrial-Dependent Pathway. J Neuroimmune Pharmacol (Sep), 13(3): 396-411.
- Sharikova AV, Quaye E*, Aalinkeel R, Park JY, Maloney MC, Desta H, Thiyagarajan R, Seldeen K, Khmaladze A, Troen B, Schwartz SA and Mahajan SD. (2018) Methamphetamine-induced mitochondrial toxicity is a major determinant of microglial apoptosis. J Neuroimmune Pharmacol (Sep), 13(3): 396-411.
- Mosleh W, Chaudhari MR, Sonkawade S, Mahajan SD, Khalil C, Frodey K, Shah T, Dahal S, Karki R, Katkar R, Blankesteijn WM, Page BJ, Pokharel S, Kim M, Sharma UC. (2018) The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study. Biomark Insights (Jun), 13: 1-10.
- Mammen MJ, Sands MF, Abou-Jaoude E, Aalinkeel R, Reynolds JL, Parikh NU, Sharma U, Schwartz SA, Mahajan SD. (2018) Role of Galectin-3 in the pathophysiology underlying allergic lung inflammation in a tissue inhibitor of metalloproteinases 1 knockout model of murine asthma. Immunology (Mar), 153(3): 387-396.
- Schwartz SA. (2018) Mitochondrial dysfunction in an aging HIV patient cohort with HIV associated neurological disorders (HAND). Journal of Neurovirology (Jan), 24.
- Sharma RK, Cwiklinski K, Aalinkeel R, Reynolds JL, Sykes DE, Quaye E, Oh J, Mahajan SD, Schwartz SA. (2017) Immunomodulatory activities of curcumin-stabilized silver nanoparticles: Efficacy as an antiretroviral therapeutic. Immunol Invest (Nov), 46(8): 833-846.
- Mahajan SD, Aalinkeel R, Parikh NU, Jacob A, Cwiklinski K, Sandhu P, Le K, Loftus AW, Schwartz SA, Quigg RJ, Alexander JJ. (2017) Immunomodulatory Role of Complement Proteins in the Neuropathology Associated with Opiate Abuse and HIV-1 Co-Morbidity. Immunol Invest (Nov), 46(8): 816-832.
- Aalinkeel R, Kutscher HL, Singh A, Cwiklinski K, Khechen N, Schwartz SA, Prasad PN, Mahajan SD. (2017) Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer‘s disease?. J Drug Targeting (Jul), 26(2): 182-193.
- Aalinkeel R, Mangum CS, Abou-Jaoude E, Reynolds JL, Liu M, Sundquist K, Parikh NU, Chaves LD, Mammen MJ, Schwartz SA, Mahajan SD. (2017) Galectin-1 Reduces Neuroinflammation via Modulation of Nitric Oxide-Arginase Signaling in HIV-1 Transfected Microglia: a Gold Nanoparticle-Galectin-1 "Nanoplex" a Possible Neurotherapeutic?. J Neuroimmune Pharmacol (Mar), 12(1): 133-151.
- Mahajan SD, Tutino VM, Redae Y, Meng H, Siddiqui A, Woodruff TM, Jarvis JN, Hennon TR, Schwartz S, Quigg RJ, Alexander JJ. (2016) C5a Induces Caspase-dependent Apoptosis in Brain Vascular Endothelial Cells in Experimental Lupus. Immunology (Aug), 148(4): 407-419.
- Aalinkeel R, Nair B, Chen CK, Mahajan SD, Reynolds JL, Zhang H, Sun H, Sykes DE, Chadha KC, Turowski SG, Bothwell KD, Seshadri M, Cheng C, Schwartz SA. (2016) Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis. Immunology (Aug), 148(4): 387-406.
- Ajay Singh , Woong Kim , Youngsun Kim , Keunsoo Jeong , Chi Soo Kang , YoungSoo Kim ,Joonseok Koh , Supriya D. Mahajan , Paras N. Prasad , and Sehoon Kim. (2016) Multifunctional Photonics Nanoparticles for Crossing the Blood–Brain Barrier and Effecting Optically Trackable Brain Theranostics. Adv. Funct. Mater. 2016, 26, 7057–7066. (Jan), 26: 7057-7066.
- Parikh, NU, Magnum, C, Aalinkeel R, Reynolds JL, Sykes DE, Mammen MJ, Sykes DE, Mahajan SD. (2016) Galectin-1 reduces neuroinflammation via modulation of the nitric oxide-arginase network in microglia: implications for a neuroprotective role in HIV associated neurocognitive disorders. Journal Of Neuroimmune Pharmacology, (Jan).
- Shen X, Bindukumar B. Nair , Supriya D. Mahajan, Xiaosheng Jiang, Jun Li, Shichen Shen, Chengjian Tu, Chiu-bin Hsiao, Stanley Schwartz and Jun Qu. (2015) New insights into the disease progression control mechanisms by comparing Long-term-non-progressors vs. Normal-progressors among HIV-1-carrying patients using an ion current-based proteomic profiling. Journal Of Proteome Research (Dec), 14(12): 5225-5239.
- Shen X, Nair B, Mahajan SD, Jiang X, Li J, Shen S, Tu C, Hsiao CB, Schwartz SA, Qu J. (2015) New Insights into the Disease Progression Control Mechanisms by Comparing Long-Term-Nonprogressors versus Normal-Progressors among HIV-1-Positive Patients Using an Ion Current-Based MS1 Proteomic Profiling. J Proteome Res (Nov).
- Mahajan SD, Parikh NU, Woodruff TM, Jarvis JN, Lopez M, Hennon TR, Cunningham P, Quigg RJ, Schwartz SA, Alexander JJ. (2015) C5a Alters Blood-brain Barrier Integrity in a Human in Vitro Model of Systemic Lupus Erythematosus. Immunology (Sep), 146(1): 130-143.
- Parikh N, Aalinkeel R, Reynolds JL, Nair BB, Sykes DE, Mammen MJ, Schwartz SA, Mahajan SD. (2015) Galectin-1 suppresses methamphetamine induced neuroinflammation in human brain microvascular endothelial cells: Neuroprotective role in maintaining blood brain barrier integrity. Brain Res (Jul).
- Gerard E, Spengler RN, Bonoiu AC, Mahajan SD, Davidson BA, Ding H, Kumar R, Prasad PN, Knight PR, Ignatowski TA. (2015) Chronic constriction injury-induced nociception is relieved by nanomedicine-mediated decrease of rat hippocampal tumor necrosis factor. Pain (Jul), 156(7): 1320-1333.
- Ignatowski TA, Aalinkeel R, Reynolds JL, Nair BB, Sykes DE, Gleason CP, Law WC, Mammen MJ, Prasad PN, Schwartz SA, Mahajan SD. (2015) Nanotherapeutic Approach for Opiate Addiction Using DARPP-32 Gene Silencing in an Animal Model of Opiate Addiction. J Neuroimmune Pharmacol (Mar), 10(1): 136-152.
- Mahajan SD, Gaekwad A, Pawar J, Tripathy S, Ghate M, Bhattacharya J, Singh HO, Schwartz SA, Paranjape R, Gangakhedkar R. (2015) Cardiac morbidity in an HIV-1 lipodystrophy patient cohort expressing the TNF-a-238 G/A single nucleotide gene polymorphism. Curr HIV Res (Jan), 13(2): 98-108.
- Mahajan SD, Gaekwad A, Pawar J, Tripathy S, Ghate M, Bhattacharya J, Singh HO, Schwartz SA, Paranjape R, Gangakhedkar R. (2015) Cardiac morbidity in an HIV-1 lipodystrophy patient cohort expressing the TNF-α-238 G/A single nucleotide gene polymorphism. Curr HIV Res (Jan), 13(2): 98-108.
- Dai L, Li N, Wei F, Li J, Liu Y, Xia W, Zhang T, Guo C, Wang W, Schwartz SA, Mahajan SD, Hsiao CB, Wu H. (2014) Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008-2011. Viral Immunol (Oct), 27(8): 392-397.
- Dai L, Mahajan SD, Guo C, Zhang T, Wang W, Li T, Jiang T, Wu H, Li N. (2014) Spectrum of central nervous system disorders in hospitalized HIV/AIDS patients (2009-2011) at a major HIV/AIDS referral center in Beijing, China. J Neurol Sci (Jul), 342(1-2): 88-92.
- Chen CK, Law WC, Aalinkeel R, Nair B, Kopwitthaya A, Mahajan SD, Reynolds JL, Zou J, Schwartz SA, Prasad PN, Cheng C. (2012) Well-defined degradable cationic polylactide as nanocarrier for the delivery of siRNA to silence angiogenesis in prostate cancer. Adv Healthc Mater (Nov), 1(6): 751-761.
- Brown P, Nair B, Mahajan SD, Sykes DE, Rich G, Reynolds JL, Aalinkeel R, Wheeler J, Schwartz SA. (2012) Single nucleotide polymorphisms (SNPs) in key cytokines may modulate food allergy phenotypes. Eur Food Res Technol (Nov), 235(5): 971-980.
- Mahajan SD, Aalinkeel R, Law WC, Reynolds JL, Nair BB, Sykes DE, Yong KT, Roy I, Prasad PN, Schwartz SA. (2012) Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int J Nanomedicine (Oct), 7: 5301-5314.
- Yong KT, Wang Y, Roy I, Rui H, Swihart MT, Law WC, Kwak SK, Ye L, Liu J, Mahajan SD, Reynolds JL. (2012) Preparation of quantum dot/drug nanoparticle formulations for traceable targeted delivery and therapy. Theranostics (Jul), 2(7): 681-694.
- Law WC, Mahajan SD, Kopwitthaya A, Reynolds JL, Liu M, Liu X, Chen G, Erogbogbo F, Vathy L, Aalinkeel R, Schwartz SA, Yong KT, Prasad PN. (2012) Gene Silencing of Human Neuronal Cells for Drug Addiction Therapy using Anisotropic Nanocrystals. Theranostics (Jul), 2(7): 695-704.
- Reynolds JL, Law WC, Mahajan SD, Aalinkeel R, Nair B, Sykes DE, Yong KT, Hui R, Prasad PN, Schwartz SA. (2012) Nanoparticle Based Galectin-1 Gene Silencing, Implications in Methamphetamine Regulation of HIV-1 Infection in Monocyte Derived Macrophages. J Neuroimmune Pharmacol (Jun).
- Aalinkeel R, Nair B, Reynolds JL, Sykes DE, Law WC, Mahajan SD, Prasad PN, Schwartz SA. (2012) Quantum rods as nanocarriers of gene therapy. Drug Deliv (May), 19(4): 220-231.
- Reynolds JL, Law WC, Mahajan SD, Aalinkeel R, Nair B, Sykes DE, Mammen MJ, Yong KT, Hui R, Prasad PN, Schwartz SA. (2012) Morphine and galectin-1 modulate HIV-1 infection of human monocyte-derived macrophages. J Immunol (Apr), 188(8): 3757-3765.
- Mahajan SD, Law WC, Aalinkeel R, Reynolds J, Nair BB, Yong KT, Roy I, Prasad PN, Schwartz SA. (2012) Nanoparticle-mediated targeted delivery of antiretrovirals to the brain. Methods Enzymol (Jan), 509: 41-60.
- Schwartz SA. (2012) Anti-HIV nanotherapeutics: promises and challenges for the future. International Journal of Nanomedicine (Jan), 7: 5301-5314.
- Nair B, Wheeler JC, Sykes DE, Brown P, Reynolds JL, Aalinkeel R, Mahajan SD, Schwartz SA. (2011) Proteomic Approach to Evaluate Mechanisms That Contribute to Food Allergenicity: Comparative 2D-DIGE Analysis of Radioallergosorbent Test Positive and Negative Patients. Int J Proteomics (Sep), 2011: 673618-673618.
- Mahajan SD, Aalinkeel R, Reynolds JL, Nair B, Sykes DE, Bonoiu A, Roy I, Yong KT, Law WC, Bergey EJ, Prasad PN, Schwartz SA. (2011) Suppression of MMP-9 expression in brain microvascular endothelial cells (BMVEC) using a gold nanorod (GNR)-siRNA nanoplex. Immunol Invest (Aug), 41(4): 337-355.
- Mahajan SD, Aalinkeel R, Reynolds JL, Nair B, Sykes DE, Law WC, Ding H, Bergey EJ, Prasad PN, Schwartz SA. (2011) Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA. Patholog Res Int (May), 2011: 719139-719139.
- Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, Schwartz SA. (2011) Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest (Mar), 40(5): 447-464.
- Reynolds JL, Mahajan SD, Aalinkeel R, Nair B, Sykes DE, Schwartz SA. (2011) Methamphetamine and HIV-1 gp120 effects on lipopolysaccharide stimulated matrix metalloproteinase-9 production by human monocyte-derived macrophages. Immunol Invest (Mar), 40(5): 481-497.
- Mahajan SD, Roy I, Xu G, Yong KT, Ding H, Aalinkeel R, Reynolds J, Sykes D, Nair BB, Lin EY, Prasad PN, Schwartz SA. (2010) Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr HIV Res (Jul), 8(5): 396-404.
- Aalinkeel R, Hu Z, Nair BB, Sykes DE, Reynolds JL, Mahajan SD, Schwartz SA. (2010) Genomic Analysis Highlights the Role of the JAK-STAT Signaling in the Anti-proliferative Effects of Dietary Flavonoid-'Ashwagandha' in Prostate Cancer Cells. Evid Based Complement Alternat Med (Jun), 7(2): 177-187.
- Bonoiu A, Mahajan SD, Ye L, Kumar R, Ding H, Yong KT, Roy I, Aalinkeel R, Nair B, Reynolds JL, Sykes DE, Imperiale MA, Bergey EJ, Schwartz SA, Prasad PN. (2009) MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res (Jul), 1282: 142-155.
- Dosch SF, Mahajan SD, Collins AR. (2009) SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro. Virus Res (Jun), 142(1-2): 19-27.
- Bonoiu AC, Mahajan SD, Ding H, Roy I, Yong KT, Kumar R, Hu R, Bergey EJ, Schwartz SA, Prasad PN. (2009) Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A (Apr), 106(14): 5546-5550.
- Reynolds JL, Mahajan SD, Aalinkeel R, Nair B, Sykes DE, Schwartz SA. (2009) Proteomic analyses of the effects of drugs of abuse on monocyte-derived mature dendritic cells. Immunol Invest (Jan), 38(6): 526-550.
- Mahajan SD, Aalinkeel R, Reynolds JL, Nair BB, Sykes DE, Hu Z, Bonoiu A, Ding H, Prasad PN, Schwartz SA. (2009) Therapeutic targeting of "DARPP-32": a key signaling molecule in the dopiminergic pathway for the treatment of opiate addiction. Int Rev Neurobiol (Jan), 88: 199-222.
- Aalinkeel R, Bindukumar B, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, Schwartz SA. (2008) The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate (Dec), 68(16): 1773-1789.
- Schwartz SA. (2008) Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells. Prostate (Oct), 68(14): 1531-1545.
- Xu G, Yong KT, Roy I, Mahajan SD, Ding H, Schwartz SA, Prasad PN. (2008) Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier. Bioconjug Chem (Jun), 19(6): 1179-1185.
- Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Adal A, Qi M, Toh J, Xu G, Prasad PN, Schwartz SA. (2008) Methamphetamine alters blood brain barrier permeability via the modulation of tight junction expression: Implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res (Apr), 1203: 133-148.
- Bernstein ZP, Dougherty T, Gollnick S, Schwartz SA, Mahajan SD, Kepner J, Sumlin A, Stewart C, Wallace P, Adal A, Walder H, Poiesz B. (2008) Photopheresis in HIV-1 infected patients utilizing benzoporphyrin derivative (BPD) verteporfin and light. Curr HIV Res (Mar), 6(2): 152-163.
- Bindukumar B, Mahajan SD, Reynolds JL, Hu Z, Sykes DE, Aalinkeel R, Schwartz SA. (2008) Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res (Jan), 1191: 1-11.
- Reynolds JL, Mahajan SD, Sykes DE, Schwartz SA, Nair MP. (2007) Proteomic analyses of methamphetamine (METH)-induced differential protein expression by immature dendritic cells (IDC). Biochim Biophys Acta (Apr), 1774(4): 433-442.
- Reynolds JL, Mahajan SD, Bindukumar B, Sykes D, Schwartz SA, Nair MP. (2006) Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human astrocytes (NHA). Brain Res (Dec), 1123(1): 226-236.
- Mahajan SD, Aalinkeel R, Singh S, Shah P, Gupta N, Kochupillai N. (2006) Endocrine regulation in asymmetric intrauterine fetal growth retardation. J Matern Fetal Neonatal Med (Oct), 19(10): 615-623.
- Reynolds JL, Mahajan SD, Sykes D, Nair MP. (2006) Heroin-Induces Differential Protein Expression by Normal Human Astrocytes (NHA). Am J Infect Dis (Jan), 2(2): 49-57.
- Mahajan SD, Hu Z, Reynolds JL, Aalinkeel R, Schwartz SA, Nair MP. (2006) Methamphetamine modulates gene expression patterns in monocyte derived mature dendritic cells: implications for HIV-1 pathogenesis. Mol Diagn Ther (Jan), 10(4): 257-269.
- Mahajan SD, Aalinkeel R, Singh S, Shah P, Gupta N, Kochupillai N. (2005) Thyroid hormone dysregulation in intrauterine growth retardation associated with maternal malnutrition and/or anemia. Horm Metab Res (Oct), 37(10): 633-640.
- Nair MP, Reynolds JL, Mahajan SD, Schwartz SA, Aalinkeel R, Bindukumar B, Sykes D. (2005) RNAi-directed inhibition of DC-SIGN by dendritic cells: prospects for HIV-1 therapy. AAPS J (Oct), 7(3): 572-578.
- Mahajan SD, Schwartz SA, Aalinkeel R, Chawda RP, Sykes DE, Nair MP. (2005) Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol (Jun), 115(3): 323-332.
- Nair MP, Schwartz SA, Mahajan SD, Tsiao C, Chawda RP, Whitney R, Don Sykes BB, Hewitt R. (2004) Drug abuse and neuropathogenesis of HIV infection: role of DC-SIGN and IDO. J Neuroimmunol (Dec), 157(1-2): 56-60.
- Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, Schwartz SA. (2004) Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res (Aug), 64(15): 5311-5321.
- Mahajan SD, Singh S, Shah P, Gupta N, Kochupillai N. (2004) Effect of maternal malnutrition and anemia on the endocrine regulation of fetal growth. Endocr Res (May), 30(2): 189-203.
- Mahajan SD, Aalinkeel R, Schwartz SA, Chawda RP, Nair MP. (2003) Effector cell mediated cytotoxicity measured by intracellular Granzyme B release in HIV infected subjects. Biol Proced Online (Jan), 5: 182-188.
- Mahajan SD, Schwartz SA, Nair MP. (2003) Immunological assays for chemokine detection in in-vitro culture of CNS cells. Biol Proced Online (Jan), 5: 90-102.
- Mahajan SD, Schwartz SA, Shanahan TC, Chawda RP, Nair MP. (2002) Morphine regulates gene expression of alpha- and beta-chemokines and their receptors on astroglial cells via the opioid mu receptor. J Immunol (Oct), 169(7): 3589-3599.
- Saker F, Voora DM, Mahajan SD, Kiliç I, Ismail-Beigi F, Kalhan SC. (1999) Effect of reduced inspired oxygen on fetal growth and maternal glucose metabolism in rat pregnancy. Metabolism (Jun), 48(6): 738-744.
Books and Book Chapters:
- Mahajan SD, You Y, Aalinkeel R, Reynolds JL, Nair, Bindukumar B, Mammen MJ, Ignatowski TA, Cheng, Chong, Schwartz SA. (2016) Biodegradable Nanoparticle-Based Antiretroviral Therapy across the Blood-Brain Barrier.
- Mahajan SD, Aalinkeel R, Reynolds JL, Nair BB, Mammen MJ, Dai L, Prasad PN, Schwartz SA. (2015) Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases. Elsevier.
Abstracts:
- Parikh NU, Aalinkeel R, Reynolds JL, Quaye E, Cwiklinski K, Sykes DE, Mammen MJ, Sharijkova, A, Khmaladze A, Schwartz SA, Mahajan SD. (2017) Methamphetamine (METH) and HIV-tat mediated oxidative stress contributes to Mitochondrial dysfunction in microglia. JOURNAL OF NEUROIMMUNE PHARMACOLOGY, (Apr)
- Aalinkeel R, Abou-Jaoude E, Parikh, N, Reynolds JL, Sykes DE, Mammen MJ, Mahajan SD, Schwartz SA. (2016) Galectin-3 in prostate cancer proliferation and metastasis. European Journal of Immunology, (Aug)
- Parikh NU, Mahajan SD, Aalinkeel R, Reynolds JL, Nair BN, Sykes DE, Mammen MJ, Schwartz SA. (2015) Galectin-1 is Neuroprotectice and Reverses Methamphetamine Induced Blood Brain Barrier Breakdown. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, (May)
- Ignatowski TA, Gerard BA, Bonoiu A, Mahajan SD, Knight III PR, Davidson BA, Bergey EJ, Prasad PN, Spengler RN. (2013) Reduction of tumor necrosis factor (TNF) in the hippocampus alleviates neuropathic pain perception. Proceedings of the 4th International Congress on Neuropathic Pain, (Jan) 29-35
Professional Memberships:
- American Society for Nanomedicine
- International Society of Neurovirology (ISNV
- International Union of Immunology Societies, (IUIS
- The Canadian Immunology Society
- The Endocrine Society
- The International AIDS Society (IAS)
- The Society of NeuroImmune Pharmacology (SNIP)
Presentations:
- "“Nanotherapeutics”." International conference Biorujivith 2021, ‘Innovations And Emerging Trends In Basic And Applied Sciences, Leading To New Entrepreneurship And Employment” hosted by School Of Sciences, Department Of Life Sciences, Garden City University, Bangalore, India in 2021. (2021)
- "Public Health Informatics in The Context of The Covid-19 Pandemic”" National Conference On Covid-19 And Its Psychological Effects Organized by Department Of Chemistry, Rajdhani College, University Of Delhi India, on 30th April 2021. (2021)
- "Nanotherapeutics: Future of Personalized Nanomedicine" Inaugural lecture for the International Lecture series-titled Multifaceted Chemistry-An Ever evolving domain of Science, organized by DeshBandhu College, University at Delhi, on Feb 14 th, 2021 (2021)
- "“Nanotherapeutics- Future Medicine- A new era of Clinical Medicine”" Bioscience for Enriching Human Life Webinar series for Faculty” Hosted by Sri Ramakrishna College, Dept of Biochemistry & Microbiology. (2020)
- "Nanotherapy for Drug addiction" Herbert Wertheim Distinguished Lectureship Series; Florida International University; Department of Immunology and Nano-Medicine at the Herbert Wertheim College of Medicine (HWCOM), FIU. (2019)
- "Neurodegeneration associated with Methamphetamine Abuse" Colloquium; SUNY Albany; College of Arts and Science (2016)
- "Nanotherapy for Drug addiction" CTRC Research Seminar; UB; CTRC Research Group (2014)
- "HIV-1 disease progression" Center for Molecular Dynamics; Center for Molecular Dynamics; Center for Molecular Dynamics (2012)
- "ART in India and its impact on HIV-1 associated Lipodystrophy" US- Fulbright; USIEF; US- Fulbright South Asian Meeting (2012)
- "HIV-1 associated Lipodystrophy" Seminar National AIDS Resaerch Research Institute ( NARI), India; NARI; HIV pathophysiology (2012)
- "Proteomic approach to evaluation of Disease Progression In Long Term Non Progressors (LTNP) of HIV-1 disease" Immunological Societies of Asia Oceania; FIMSA; FIMSA (2012)
- "Nanotherapy for Drug addiction." International Conference on Molecular Medicine; Vellore Institute of Technology; MOLMED-2012 (2012)
- "“Modulation of Tight junction expression by an MMP-9 nanoplex: Implications for maintaining Blood Brain Barrier integrity in HIV-1 encephalitis." International Symposium on HIV and Emerging Infectious Diseases.; FIMSA; HIV and Emerging Infectious Diseases. (2010)
- "Enhancing the Transversing Efficiency And Efficacy Of the Anti Retroviral Drug “Saquinavir” Using Nanotechnology: Implications For Nanotherapeutics In Neuro-Aids" 4th International Workshop on HIV-1 Persistance; HIV-1 resistance & Persistance; Nanotherapeutics In Neuro-Aids (2009)
Service Activities:
- NIDA Avenir Program (DP1) Special Emphasis Panel (SEP) ZDA1 IXR-Q (04) S February 23-24th, 2022; Special Emphasis Panel (SEP) member (2022)
- NIH-NIAID, “Emergency Awards for COVID-19/SARS-CoV-2 ZAI1-JHM-X-S3; Review Panel Member (2021)
- NIH-NIAID HIV/ AIDS Biological-F17A-B (20) Review Panel Member – July 13, 2021; Review Panel member (2021)
- AIDS and AIDS Related Research (AARR) IRG 2021/01 ZGR1 AARR-B (02) - Dec 11, 2020.; Review Panel Member (2020)
- NIH-NIMH “BRAIN Initiative” – March 13, 2020; Review panel Member (2020)
- IP Forum Faculty Facilitator; Faculty Facilitator (2020–present)
- HIV immunology and pathogenesis/vaccines/microbiome/neuro-AIDS2019/10 ZRG1 AARR-P (02) M – July 30, 2019; Member Review Panel (2019)
- Neuroscience and Bioengineering SEP (ZRG1 ETTN-K (02) SEP – June 7, 2019; Member Review Panel (2019)
- Annual Participation in the Science Teachers Association of New York State (STANYS) conference to promote awareness in STEM education; Invited Speaker (2018–2019)
- Standing Study Section Member 2019/01 ZRG1 F02A-K (20) L: Oct 18-19, 2018 March 7-8, 2019 May 28-29, 2019 Oct 11-12, 2019 Feb 12-13, 2020 June 25-26, 2020 Oct- 21-22, 2021; NIHStudy Section Member (2018–present)
- HIV and Drug Abuse: Small Grant Applications: A-START program - 2017/10 ZRG1 AARR-N (91) P – June 12, 2017; July 30, 2018; Session Chair, Member Review Panel (2018)
- Research Symposium Judge for CSTEP Summer Research Program; Research Symposium Judge for CSTEP Summer Research Program (2017–present)
- AIDS and Related Research (AARR) Integrated Review Group; -2016/10 ZRG1 AARR-N (91) S – July 2016; Member Review Panel (2016)
- Medicine Research Day; Judge (2016–present)
- NSF- GRFP Neuroscience Panel; National Science Foundation (NSF);; Panel Member (2016–2020)
- NIH CTSA; CTSA Pilot grant program;; Grant Reviewer (2015)
- Faculty Senate Member second Term Term 1-2015-2018 Term 2- 2021-2024; Member (2015–2024)
- NIDA ZDA1 HXO-H (01); Member Scientific Review Group: NIH Pathway to Independence Award;; Grant Reviewer (2015)
- NIH- RCMI; Centers in Minority Institutions (RCMI) Translational Research Network;; Grant Reviewer (2015)
- NIDA ZDA1 HXO-H (05); Member Scientific Review Group: NIH Pathway to Independence; Agenda Seq Num – 280299, March 11, 2015 ;; Grant Reviewer (2015)
- NIH- RCMI; Research Centers in Minority Institutions (RCMI) Translational Research Net; Reviewer for NIH grants awarded to Research Centers in Minority Institutions (RCMI) Translational Research Network (RTRN)- 2014,;; External Reviewer (2014–2015)
- NIDA- ZDA1 HXO-H (04); Member Scientific Review Group: NIH Pathway to Independence Award (K99/R00;; Grant Reviewer (2014)
- Faculty Council Member; Member (2014–2017)
- Faculty Council; Member (2014–2019)
- Coordinator for Clinical trials for the Division of Allergy, Immunology & Rheumatology Coordinator for Clinical trials for the Division of Allergy, Immunology & Rheumatology Ongoing trials in the Division GAM 5-28 Octagam Research trial Impact of Lung Flute Therapy on Asthma (completed); Advisor (2014–2015)
- International Society of Neurovirology (ISNV) Member; Member (2014–present)
- VA; Reviewer for Veteran Adminstration, Western New York Health Care System-; Reviewer for Veteran Adminstration, Western New York Health Care System- 2013 VAWNYHS Institutional Animal Care and Use Committee (IACUC) and Research & Development Committee (RDC);; Grant Reviewer (2013)
- The Endocrine Society; Associate Member (2012–present)
- NIDA; Member Scientific Review Group: ZDA1 SXC-E 12 1; NIDA Cutting-Edge Basic Research Awards (CEBRA) (R21) –December 2011;; Ad Hoc Reviewer (2011)
- VA Western New York Healthcare System- VA Research Day; Judge (2011)
- The International AIDS Society (IAS); Associate Member (2010–present)
- American Society for Nanomedicine; Member (2010–present)
- The Society of NeuroImmune Pharmacology (SNIP); Member (2008–present)
- Director of Research Division of Allergy, Immunology & Rheumatology; Director (2006–present)
- Reviewer for the Scientific journals Journal Of Neuroimmune Pharmacology Nutrition AIDS Research & Therapy Expert Review of Endocrinology and Metabolism International Journal of Biomedical Science Nanomedicine BMC genomics AIDS Research and Human Retroviruses Research Reports in Clinical Cardiology Neurobehavioral HIV Medicine BMC Neurology International Journal of Nanomedicine African Journal of Pharmacy and Pharmacology Journal of Clinical Immunology Journal of the Taiwan Institute of Chemical Engineers Science of Advanced Materials European Food Research and Technology NANO Biomaterials Science; Reviewer (2006–present)
- The Canadian Immunology Society - International Union of Immunology Societies, (IUIS); Member (2006–present)